Lacidipino Teva

Lacidipine, the active ingredient in Lacidipino Teva, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lacidipino Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a calcium channel blocker used in the management of high blood pressure and related cardiovascular conditions. - Hypertension: reduces elevated systolic and diastolic blood pressure. - Primary hypertension: helps achieve target blood pressure levels in essential hypertension. - Secondary hypertension: can be added to other therapies when blood pressure elevation is due to an identifiable cause.

Lacidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness, especially after standing. - Nausea or abdominal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: swelling of the face, lips, tongue, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Blood dyscrasias: rare blood cell abnormalities.

Before prescribing Lacidipino Teva, clinicians should consider several safety aspects. - Blood pressure monitoring: check baseline and follow‑up readings. - Liver function: assess hepatic enzymes in patients with liver disease. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Elderly patients: start at lower dose and monitor for dizziness. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine levels. - Other calcium channel blockers: additive vasodilatory effect leading to hypotension. - Grapefruit juice: can raise plasma concentrations. - Concurrent antihypertensives with potent vasodilatory action: risk of severe hypotension. - Rifampicin or other CYP3A4 inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- NSAIDs: may blunt antihypertensive response. - Diuretics: may increase risk of electrolyte imbalance. - Beta‑blockers: monitor heart rate and blood pressure. - ACE inhibitors or ARBs: watch for additive blood pressure lowering. - Lipid‑lowering agents (e.g., statins metabolized by CYP3A4): monitor for increased statin exposure.